# OnCo record nct07554456 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07554456/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07554456", "NCT07554456" ;
  schema:name "A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)"@en ;
  schema:alternateName "PANKU-Esophagus02"@en ;
  schema:description "A phase 2/3 trial of Tislelizumab and Cisplatin in oesophageal cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07554456/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07554456> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2/3" ;
  schema:startDate "2026-06-09" ;
  onco:cancers <https://onco.cc/cancers/esophageal/>, <https://onco.cc/cancers/oesophageal-squamous-cell-carcinoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/tislelizumab/>, <https://onco.cc/drugs/cisplatin/> ;
  onco:companies <https://onco.cc/companies/systimmune/> .